Table 4. Characteristics by Cardiac Magnetic Resonance (CMR)-derived Median Left Ventricular Mass Index (LVMi).

Variable	CMR-LVMi (<55 mg/m2) (n=45)	CMR-LVMi (>55 mg/m2) (n=46)	p Value
Age of chemotherapy (yrs)	42 (18)	43 (17)	0.69
Male	24 (45%)	29 (55%)	0.39
Chest radiation	19 (63%)	11 (37%)	0.07
Anthracycline dose (mg/m )	317 (76)	235 (63)	<0.0001
Major adverse cardiac events	40 (77%)	12 (23%)	<0.0001
Chemo to heart failure (months, mean, mths)	91 (81)	105 (90)	0.43
Heart failure stage C	39 (52%)	35 (48%)	0.28
Diabetes Mellitus	6 (55%)	5 (45%)	0.75
Hypertension	18 (51%)	17 (49%)	0.83
Atrial fibrillation	10 (50%)	10 (50%)	1.00
Systolic blood Pressure (mmHg)	116 (15)	115 (17)	0.51
Diastolic blood Pressure (mmHg)	73 (13)	70 (11)	0.21
Heart rate (beats/min)	71 (13)	74 (13)	0.37
Medication
ACE/ARB	38 (51%)	37 (49%)	0.78
Beta-blocker	38 (51%)	37 (49%)	0.76
Spironolactone	13 (62%)	8 (38%)	0.12
QRS duration (ms)	96 (14)	96 (18)	0.99
Glomerular filtration rate (ml/min/1.73m )	72 (23)	84 (23)	0.02
Echocardiography:
Estimated pulmonary artery systolic pressure (mmHg)	33 (10)	33 (10)	0.95
Left ventricular mass index by echo (gm/m2)	80 (19)	76 (16)	0.33
Cardiac Magnetic Resonance
Indexed left ventricular end diastolic volume (ml/m2)	97 (21)	88 (21)	0.05
Indexed left ventricular end systolic volume (ml/m )	63 (18)	55 (14)	0.04
Left ventricular ejection fraction (%)	36 (8)	36 (7)	0.62
Indexed right ventricular end diastolic volume (ml/m2)	80 (20)	77 16)	0.38
Indexed right ventricular end systolic volume (ml/m )	44 (15)	42 (15)	0.56
Right ventricular ejection fraction (%)	45 (9)	46 (10)	0.68
Relative T2 signal intensity	1.4 (0.2)	1.5 (0.2)	0.36
Late gadolinium enhancement	3 (7%)	2 (4%)	0.56
Late gadolinium enhancement volume	8.9 (4.6)	4.4 (1.1)	0.22

All data are mean (SD) unless otherwise indicated